More recently, it has been proposed that inhibiting the inflammasomes pathways and/or pyroptosis in COVID-19 therapy would be an efficient strategy to decrease SARS-CoV-2 virulence and NLRP3-mediated inflammation for treatment of severe COVID-19 disease (Freeman and Swartz, 2020). The gene discussed is NLRP3; the disease is COVID-19.